Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 11

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Oncol. Nov 24, 2025; 16(11): 111983
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.111983

Table 3 Artificial intelligence-prioritized therapies linked to genomic features in each blast crisis chronic myeloid leukemia cluster

Cluster	Targeted therapies
Cluster 1	Olaparib, erlotinib, nutlin-3
Cluster 2	Ivosidenib, azacitidine, decitabine
Cluster 3	Ruxolitinib, colony-stimulating factor 1 receptor inhibitors, N-acetylcysteine

Citation: AlGarni A, Alanazi N, AlMukhaylid S, Alqahtani S, Almasoudi H, Samir Taleb Y, Alkhamis N, Shaheen S, Haji Siyal A, Aleem A, Naeem R, Shammas MA, Saglio G, Alroweilly D, Hussain A, Iqbal Z. Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing. World J Clin Oncol 2025; 16(11): 111983
URL: https://www.wjgnet.com/2218-4333/full/v16/i11/111983.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i11.111983

AlGarni A, Alanazi N, AlMukhaylid S, Alqahtani S, Almasoudi H, Samir Taleb Y, Alkhamis N, Shaheen S, Haji Siyal A, Aleem A, Naeem R, Shammas MA, Saglio G, Alroweilly D, Hussain A, Iqbal Z. Omics and artificial intelligence integration for stratifying blast crisis CML using COSMIC signatures and pan-cancer precision drug repurposing. World J Clin Oncol 2025; 16(11): 111983 [PMID: 41355924 DOI: 10.5306/wjco.v16.i11.111983]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.